InCytu is a therapeutic device engineering company developing immunotherapeutic and tissue regeneration products aimed at transforming personalized medicine. Its core product is the Cellarium platform, an intelligent biopolymer system originally developed in Professor David Mooney's lab at Harvard University. Cellarium is designed to be placed in situ to attract, educate, manipulate and locally re-deliver specific, functionally optimized and physiologically correct cells, harnessing and amplifying the body's natural processes. The company positions these technologies to enable personalized immunotherapeutic and tissue-regeneration interventions. Financially, InCytu recently raised $1.86 million in a new equity funding round, according to SEC filings. Eleven separate investors participated in the offering; no operating metrics or revenue figures were disclosed in the article.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2012